Varicella zoster virus vaccine live - sanofi pasteur

Drug Profile

Varicella zoster virus vaccine live - sanofi pasteur

Alternative Names: Chickenpox vaccine - sanofi pasteur

Latest Information Update: 24 Jan 2014

Price : $50

At a glance

  • Originator Osaka University
  • Class Varicella vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Varicella zoster virus infections

Most Recent Events

  • 23 Jan 2014 Withdrawn for Varicella zoster virus infections in France (Injection) prior to January 2014
  • 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 27 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top